Polaryx Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Polaryx Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Polaryx Therapeutics, Inc. Common Stock (PLYX) has a Cash Flow-to-Debt Ratio of -1.57x as of June 2026, meaning its operating cash flow of $-1.37 Million could theoretically repay -2% of its total liabilities ($873.00K) in one year. See PLYX FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Polaryx Therapeutics, Inc. Common Stock (2023–2025)
Cash flow-to-debt ratio of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025. Historical debt coverage capacity for Polaryx Therapeutics, Inc. Common Stock across 3 annual periods. Also explore Polaryx Therapeutics, Inc. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
Polaryx Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2023–2025)
Polaryx Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2023 to 2025. Year-by-year debt coverage analysis for Polaryx Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see PLYX cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.61x | $-3.94 Million | $855.00K | ▲ +48.2% |
| 2024 | -8.90x | $-2.57 Million | $289.00K | ▼ -5241.9% |
| 2023 | -0.17x | $-173.00K | $1.04 Million | — |